Bone and Mineral Metabolism Disorders News

In the course of 18 months, supplementation with cholecalciferol did not attenuate vascular calcification progression in patients with chronic kidney disease and vitamin D insufficiency, though it did restore 25-hydroxyvitamin D levels.

Ferric citrate may be more effective than ferrous sulfate for treating iron deficiency in patients with chronic kidney disease, according to this study.

A review of published studies revealed hip and nonvertebral fracture risks increased for patients with chronic kidney disease stages G3a-G5D, leading researchers to suggest CKD be considered as an additional risk factor for fractures.

Researchers found no difference in coronary artery calcification progression between patients with chronic kidney disease and secondary hyperparathyroidism who were randomized to either calcitriol or paricalcitol.

For patients with kidney disease, calcimimetic agents lowered parathyroid hormone levels in the short term, with each agent consisting of a different side-effect profile, according to a systematic study review.

Long-term use of unfractionated heparin may be associated with the loss of lumbar spine bone mineral density in patients undergoing maintenance hemodialysis treatment, according to a published study.

The trajectories of serum sodium levels in hospitalized patients may help predict in-hospital mortality and mortality risk at 1 year, with the highest risk of death found when serum sodium fluctuated “considerably,” according to this study.

The FDA has updated the dosing regimen for Lokelma to allow treatment of hyperkalemia in patients with end-stage kidney disease who are on chronic hemodialysis.

A study involving participants from Australia, Hong Kong, the United Kingdom and the United States, revealed what is most important to patients with glomerular disease and their caregivers. The highest-rated priorities were related to kidney health and survival, as well to the ability to actively participate in their lives and the impact on family members.

Sucroferric oxyhydroxide treatment in patients on hemodialysis resulted in improved serum phosphorus control, according to a speaker at the virtual National Kidney Foundation Spring Clinical Meetings.